Mercer, a U.K.-based producer of medical equipment, is working on a new medical product for patients in Israel, the United States and Israel.
According to the company, it will be a standard-sized and easy-to-use 3D printer that can be used for medical imaging.
Mercer is also developing a medical device that uses ultrasound to make blood clotting.
The device, called a vascular endothelial growth factor (VEGF) microarray analyzer, can be attached to a patient’s finger to detect the presence of blood clots in the veins, arteries, or joints.
The VEGF microarray analysis device was developed by Mercer and will be tested on Israeli patients, the company said.
The technology is currently in the clinical trials phase.
The Israeli company, Merck, has already started trials of the VEGGF microarray device, which is expected to be in use in Israel by 2020.
The Merck vascular endothelium-growth factor assay is already available in Israel for patients with cancer.
Merck, which makes several products for the health industry, has been pushing for more research into vascular endothelinas for several years.
It recently won a $1.3 billion contract with the U to conduct research in the field.
In a statement, Mercer said that it has been working on this project for the last several years, and is now working on its first prototype, which will be available for use in clinical trials by 2020 or 2021.
The company also said that its new microarray test is able to detect blood clotting and clotting disorders in the body and in the circulatory system, a first in the medical industry.
“We are excited to be working with Israel on a breakthrough device that will allow us to quickly and safely detect and quantify blood clumps,” said Mercer CEO Richard Smith.
“Mercer will also be testing the VEGA-1 in clinical trial settings in Israel.”
The company said that the Vega-1 will help the Israeli medical community better understand the impact of bleeding on the body.
Mercers new device, the VGA-1, will be used in the Israeli trials to measure blood clumping, and will also offer insight into vascular disorders, said Merck’s executive vice president of development, Daniel Toth.
The first phase of clinical trials for the VMG-1 and VGA will be conducted by the end of the year, and Mercer expects to be able to test the VAG-1 by the middle of 2018.
In the next phase, the Israeli company is hoping to use the Vaga-1 to monitor the function of blood vessels, and to identify vascular disorders.
Merchants new VEG-1 is expected in clinical tests by 2020 and is expected for clinical use in Israeli hospitals by 2021, according to the statement.